****

EUROPEAN ASSOCIATION OF HOSPITAL PHARMACISTS

Board Member Portfolios

**APPENDIX 1- Strategic Objective Leads**

|  |  |  |
| --- | --- | --- |
| **High Level Objective** | **Priority** | **Lead/Co-lead** |
| Effective Communication Platform | 1 | JP/JDG |
| Position and Influence of EAHP- EU  | 1\*  | RP |
| Empowerment & Mobilization of Members | 1\* | TMG |
| EAHP Statements Implemented | 1 | JP |
| Competent & Sufficient Workforce/ Education Framework | 1 | Existing CTF4 board members already |
| Improve Financial Position | 2 | PH |
| Horizon Scanning, Proactive & Agile | 3 | ALL |
| Operational Platform & Structure Developed | 3 | JP/JDG |

**APPENDIX 2. EAHP projects/tasks**

|  |  |  |  |
| --- | --- | --- | --- |
| **Topic area** | **Time commitment** | **Current BM lead** | **Future** |
| **Finances** | **Low to Medium:** Approval of expenditures, review of quarterly financial reports in preparation for GA, also in charge of staff salaries, benefits, SFIs, COD, Internal rules | PH | **Lead** - PH |
| **General Assembly** | **Low:** Chair of annual GA | TMG | **Lead** – TMG**Co-lead** - JP |
| **EJHP (journal)** | **Low:** Attendance to management committee meetings and decision making regarding journal changes | JP, JS and PH alternate if others cannot attend | JP, PH,FJ & JDGEAHP governance dictates abovePlus appropriate board member as an alternate topic dependent |
| **EMA representation** | **Low to Medium:** Occasional meetings at EMA. | JP and others depending on topic | **Lead** - RF for next 12 months**Co-lead** JPAnd topic dependent Board Member (projects are all time limited) |
| **FIP/WHO representation** | **Low:** Occasional events and communications | JP | **Lead** – JP**Co-lead** - RM  |
| **Congress organizing committee (OC)** | **Low:** Decision making only when new ideas presented | JP, PH, KN | JP, PH, KN & JDGAccording to internal rules/COD |
| **Scientific Committee (SC)** | **High:** Regular review of emails (each week) and tracking of multiple projects plus attendance to meetings and responsibility for congress/academy content | KN | **Lead**- KN**Co-Lead** - JDGKN to begin succession planning  |
| **Communications and web site** | **High:** Only necessary when new ideas presented |  | **LEAD** JP **Co-lead** JDG comms objective |
| **Recruitment & mobilization of members** | **Medium** Only applicable as missing countries form their associations | TMG | **Lead** - TMGSupport by all  |
| **Statement implementation steering committee** | **Low to Medium but will become high:** Occasional meetings. | JP, JS, KN & JDG | **Lead** – JP**Co-lead** – Project leaderSupport all |
| **Topic area** | **Time commitment** | **Current BM lead** | **Future** |
| **Student internship programme/EPSA involvement** | **Medium:** Decision making only when new ideas presented, follow up on progress, maintain student internship progamme |  | **LEAD** - AB**CO-LEAD** - OFFICE |
| **Policy and advocacy – weekly update with president** | **High:** Regular review of emails (sometimes several times per week) and tracking of multiple projects plus attendance to meetings and content | JP | **Lead** – JP**Co-lead** - RP |
| **Surveys** | **High:** Regular review of emails (sometimes several times per week) and tracking of projects, meetings, publications of results |  | **LEAD**- PH **CO-LEAD** - AB & JS |
| **Coordination with other European pharmacy organisations? (PGEU, EIPG, ESCP, PCNE, EAPT etc.)** | **Low to Medium:** Occasional meetings. |  | **Lead**- JP**Co-lead** – RP & officeTMG - PCNE |
| **CTF steering committee, specialization, professional card** | **High:** Regular review of emails (each week) and tracking of multiple projects | JP, KN, JS, RF & Office | JP, KN, JS, RF & Office |
| **CTF Working Groups** | **High:** Regular review of emails (each week) and follow up on action items | JP, KN, JS, RF & office | JP, KN, JS, RF & office |
| **Falsified Medicines Directive** | **Medium to High:** Regular review of emails (each week) and developments |  | **LEAD** - RM**CO-LEAD** - AS |
| **Medicines shortages** | **Medium to High:** Regular review of emails (each week) and tracking of multiple projects. If COST bid successful, topic will certainly become high in time commitment. |  | **LEAD** - AB**CO-LEAD** - OFFICE |
| **Medicines barcoding/bedside scanning issue** | **Medium to High:** Regular review of emails and tracking of multiple projects |  | **LEAD** - RMCO-LEAD - OFFICE |
| **Clinical trials** | **Low:** Issue mostly now involves tracking of EMA clinical trials regulation implementation activity and occasional international development |  | **LEAD** - FV+ EMA REP AS APPROPRIATE |

|  |  |  |  |
| --- | --- | --- | --- |
| **Topic area** | **Time commitment** | **Current BM lead** | **Future** |
| **Medical Devices** | **Low:** Issue mostly now involves tracking of ongoing device regulation debates in Parliament and trilogue negotiations |  | **LEAD**- AS**CO-LEAD**- AB |
| **eHealth/mHealth/ IT/IHE** | **Low:** Occasional Commission events and consultations |  | **LEAD**- RM**CO-LEAD** -AS |
| **Antimicrobial resistance** | **HIGH:** Occasional ECDC, WHO and Commission events. Scope for EAHP to raise its profile further on this topic however. |  | **Lead** - TMG**Co-lead** - KN |
| **Medicines pricing & Austerity** | **Low to Medium:** Occasional industry and Commission events. Scope for time commitment to rise if any solid EU initiatives in the area emerge. |  | **LEAD**- JS**CO-LEAD** - FJ |
| **Ageing society** | **Low:** Occasional Commission events.  |  | **LEAD** – AS**CO-LEAD** - OFFICE |
| **Biosimilars** | **Medium:** Commission, industry, EMA and some patient groups very interested in the area |  | **LEAD**- FJ**ScCo-lead** : Antonio Gouveia |
| **Cancer** | **Low to Medium:** Plenty of events and initiatives on this topic should EAHP wish to take up such opportunities. |  | **LEAD**- JS**ScCo-lead** : Antonio Gouveia TO BE ASKED |
| **Rare Diseases (incl orphan drug issues)** | **Low to Medium:** Orphan drug regulation (EMA, Commission) and cross border healthcare directive (e.g. establishment of European Reference Networks of specialized hospitals) main topics in this area that EAHP could become more present within. |  | **LEAD** -TMG**ScCo-lead**- FV |
| **Patient safety** | **Low:** Occasional Commission or Parliament event. European Patient Safety Foundation appears to have gone quiet. |  | **LEAD** – RF**CO-LEAD** - AB |
| **Personalised Medicines** | **Low to medium:** European Alliance for Personalised Medicine, some Governments (e.g. Luxembourg) and patient and healthcare professional groups keen to engage EAHP on this topic. |  | **LEAD** – FJ**Co-lead** – TBD? |

**EAHP Board Member Lead for Member Countries**

Joan Peppard – Ireland

Aida Batista – Portugal, Spain, Italy

Tajda Miharija Gala – Slovenia, Greece, Croatia, Serbia, Montenegro, Bosnia Herzegovina, FYROM

Frank Jorgensen – Norway, Iceland, Finland, Sweden, Denmark

Rob Moss – France, Turkey, UK, The Netherlands

Kees Neef – Belgium, Luxembourg, Malta

Andras Sule – Hungary, Austria, Romania, Bulgaria

Petr Horak – Czech Republic, Latvia, Lithuania, Estonia

Juraj Sykora – Slovakia, Poland, Germany, Switzerland